Publicacions en col·laboració amb investigadors/es de Copenhagen University Hospital (93)

2024

  1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

  2. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  3. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  4. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

  5. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 7, pp. 1891-1908

  6. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis

    Blood, Vol. 144, Núm. 8, pp. 873-887

  7. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol

    Journal of Headache and Pain, Vol. 25, Núm. 1

  8. Global cross-sectional survey on neonatal pharmacologic sedation and analgesia practices and pain assessment tools: impact of the sociodemographic index (SDI)

    Pediatric Research

  9. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 981-992

  10. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  11. Parents in Neonatal Pain Management—An International Survey of Parent-Delivered Interventions and Parental Pain Assessment

    Children, Vol. 11, Núm. 9

  12. Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic

    Archives of Gynecology and Obstetrics, Vol. 310, Núm. 1, pp. 577-586

  13. Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe

    International Journal of Gynecological Cancer

  14. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer–a plain language summary

    Future Oncology, Vol. 20, Núm. 22, pp. 1531-1544

  15. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

    Nature Medicine, Vol. 30, Núm. 7, pp. 2020-2029

  16. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701

2023

  1. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

    Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229

  2. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  3. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

    Cancers, Vol. 15, Núm. 13

  4. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347